Pay in 4 interest-free payments of $7.28 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Individual responses vary, but certain factors may make one medication more suitable
Immunologically, IL-4, IL-5, IL-13, and OVA-specific IgE were significantly reduced
Study 1: The SURMOUNT-1 Trial (Obesity) Title: TZ Once Weekly for the Treatment of Obesity Summary: This landmark Phase 3 trial demonstrated that Tirzepatide achieved substantial reductions in body weight (up to 20.9%) in non-diabetic subjects, significantly outperforming placebo
The outcomes from secondary analyses were generally consistent with those from the primary analysis
US$ 28.87
US$ 26.60
US$ 20.54
US$ 26.40
US$ 22.49
US$ 20.33
